Lurasidone

Introduction Overview

Generic Name

lurasidone

Brand Name

Latuda

Dosage Form

oral tablet (120 mg; 20 mg; 40 mg; 60 mg; 80 mg)

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption: Lurasidone is administered orally and requires co-administration with food to enhance its bioavailability, with at least 350 calories recommended to optimize absorption. The oral bioavailability is significantly increased when taken with food compared to fasting conditions, supporting food intake guidelines to ensure consistent and adequate plasma levels. Peak plasma concentrations are typically achieved within 1 to 3 hours after ingestion, reflecting relatively rapid absorption. Pharmacokinetic studies have shown minimal variability in absorption when taken with food of sufficient caloric content, ensuring predictable therapeutic levels.

Distribution: Following absorption, lurasidone exhibits extensive distribution widely throughout body tissues, with a high volume of distribution indicative of significant tissue penetration particularly in the central nervous system, facilitating its antipsychotic effects. Lurasidone is highly protein-bound (~99%), primarily to albumin and alpha-1 acid glycoprotein, which influences its free (active) fraction in the plasma. Its lipophilic nature supports efficient crossing of the blood-brain barrier. Distribution can be influenced by factors such as age, body weight, and protein levels, which may require clinical monitoring in certain populations.

Metabolism: Lurasidone undergoes extensive hepatic metabolism, principally via cytochrome P450 isoenzyme CYP3A4, leading to the formation of pharmacologically active and inactive metabolites. This metabolism emphasizes the criticality of avoiding strong CYP3A4 inhibitors or inducers to prevent significant alterations in drug exposure. Metabolic pathways include oxidative N-dealkylation, hydroxylation, and sulfoxidation. The potential for drug-drug interactions is notable, especially with antifungals (e.g., ketoconazole), antibiotics (e.g., clarithromycin), and anticonvulsants (e.g., carbamazepine), necessitating dose adjustments or avoidance.

Elimination: Elimination of lurasidone and its metabolites occurs primarily via fecal (approximately 80%) and to a lesser extent renal (approximately 9%) excretion routes. The terminal elimination half-life ranges roughly 18 to 40 hours, supporting once-daily dosing schedules. Clearance is influenced by hepatic function; thus, patients with hepatic impairment may exhibit altered elimination and require careful dose adjustments. Steady-state concentrations are achieved within a few days of consistent dosing. Clinical implications include the necessity to monitor patients for accumulation and potential toxicity, especially in populations with compromised liver or renal function.

Dosage Forms

Available Dosage Forms: Lurasidone is commercially available as oral tablets in multiple strengths to tailor treatment to individual patient needs and therapeutic response. These formulations include 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg tablets. All tablets are intended for oral administration and must be taken with food to ensure optimal absorption.

Dosages for Adults and Adolescents: For the treatment of schizophrenia in adults and adolescents aged 13 years and older, initial dosing commonly starts at 40 mg once daily with food, with titration based on clinical response and tolerability up to a recommended dose range of 40 to 80 mg daily. For bipolar depression treatment in adults and children aged 10 years and older, dosing often begins at 20 mg once daily with food, with upward titration guided by efficacy and side effect profile, typically not exceeding 120 mg per day. Frequency of administration is generally once daily.

Specific Patient Populations: Dose adjustments or clinical monitoring is warranted in specific groups including those with hepatic or renal impairment, older adults, and pediatric patients. Lurasidone dosing in hepatic impairment may require reduction due to decreased clearance. While lurasidone is not approved for children under 10 years for bipolar depression or under 13 years for schizophrenia, safety and efficacy profiles inform careful consideration in adolescent use. Pregnant or breastfeeding women require individualized risk-benefit assessment, and the drug is not recommended without medical supervision. The low risk of weight gain and metabolic effects in this population makes it favorable compared to other atypical antipsychotics in select cases.

Mechanism Of Action

Lurasidone functions primarily as a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors, which underpins its efficacy in treating schizophrenia and bipolar depression. By blocking D2 receptors in mesolimbic pathways, the drug exerts antipsychotic effects, alleviating positive symptoms such as hallucinations and delusions. Its antagonism of 5-HT2A receptors contributes to improvement in negative and cognitive symptoms as well as mood stabilization, differentiating it from typical antipsychotics.

Additionally, lurasidone exhibits high affinity for serotonin 5-HT7 receptors, acting as an antagonist that is thought to contribute to improved cognition and antidepressant effects observed in clinical studies. It also has moderate antagonistic activity at 5-HT1A receptors, which may aid in anxiolytic and mood-modulating effects. Unlike many other atypical antipsychotics, lurasidone lacks significant affinity for histamine H1 and muscarinic cholinergic receptors, which results in a reduced side effect profile concerning sedation, weight gain, and anticholinergic effects.

At the cellular level, receptor blockade by lurasidone modulates intracellular signaling pathways, including cyclic AMP and phosphatidylinositol pathways, influencing neurotransmitter release and neuronal excitability. This modulation helps restore balance among dopaminergic, serotonergic, and other neurotransmitter systems implicated in psychosis and mood disorders. Its receptor profile has been validated through in vitro and in vivo studies demonstrating potent receptor binding, favorable pharmacodynamics, and clinical efficacy in randomized controlled trials.

Clinically, the mechanism of lurasidone translates to effective treatment of psychotic symptoms while minimizing adverse metabolic and sedative effects typical of older antipsychotics. The distinctive serotonergic actions also support its approved use in bipolar depression, offering an antidepressant effect that is augmented when combined with mood stabilizers such as lithium or valproate. Comparative studies highlight its beneficial tolerability and efficacy profile relative to other atypical agents such as olanzapine, risperidone, and quetiapine.

Pharmacological Actions

Selective antagonism of dopamine D2 receptors to reduce psychotic symptoms.
Strong antagonism at serotonin 5-HT2A receptors contributing to mood stabilization and negative symptom improvement.
Antagonistic activity at serotonin 5-HT7 receptors linked to cognitive enhancement and antidepressant effects.
Partial antagonism at serotonin 5-HT1A receptors providing anxiolytic and mood-regulating benefits.
Minimal affinity for histamine H1 receptors, reducing sedation and weight gain risk.
Negligible muscarinic cholinergic receptor activity, minimizing anticholinergic side effects.
Modulation of intracellular signaling cascades impacting neurotransmitter balance.
Effective blood-brain barrier penetration facilitating central nervous system activity.
Low risk of metabolic disturbances compared to other atypical antipsychotics.
Long half-life allowing once-daily dosing for improved compliance.
Reduction of psychotic, depressive, and manic symptoms in schizophrenia and bipolar disorder.
Improvement in cognitive functioning through serotonergic mechanisms.
Potential neuroprotective effects via receptor interactions and signaling modulation.

Therapeutic Or Clinical Uses

Treatment of schizophrenia in adults and adolescents aged 13 years and older.
Management of depressive episodes associated with bipolar disorder in adults and children aged 10 years and older.
Adjunct therapy combined with mood stabilizers (e.g., lithium or valproate) in bipolar depression.
Off-label use in schizoaffective disorder under clinical discretion.
Potential cognitive symptom improvement in schizophrenia as part of comprehensive therapy.
Alternative antipsychotic with a favorable metabolic profile for patients at risk of weight gain.
Use in treatment-resistant depression adjunctively where approved.
Management of negative and cognitive symptoms linked to psychotic disorders.
Therapeutic option in patients intolerant to other atypical antipsychotics due to sedation or anticholinergic effects.
Maintenance treatment to prevent recurrence of mood episodes in bipolar disorder.
Reduction of anxiety symptoms associated with psychotic or mood disorders.
Treatment option for adolescents with early onset schizophrenia under careful monitoring.
Pharmacologic component in multidisciplinary management of bipolar depression.

Side Or Adverse Effects

Drowsiness and somnolence, commonly observed among patients.
Weight gain, generally minimal compared to other atypical antipsychotics.
Extrapyramidal symptoms including tremors, muscle stiffness, and slowed movements.
Akathisia characterized by restlessness and an inability to remain still.
Nausea and vomiting with variable incidence.
Insomnia or other sleep disturbances in some patients.
Runny nose or upper respiratory tract symptoms.
Orthostatic hypotension causing dizziness or light-headedness.
Rare occurrence of tardive dyskinesia, particularly with long-term or high-dose use.
Potential for hyperglycemia and metabolic changes; monitoring recommended.
Seizures, although infrequent, may occur especially in predisposed individuals.
Rare serious movement disorders such as neuroleptic malignant syndrome.
Hormonal changes including irregular menstrual periods or breast changes in women, and breast swelling or impotence in men.
Low white blood cell count presenting as fever, sore throat, or infection risks.
Manic episodes, including symptoms of increased energy, decreased need for sleep, and risk-taking behavior.

Precautions

Use cautiously in patients with a history of seizures or conditions lowering seizure threshold.
Monitor blood glucose in patients with diabetes or risk factors for hyperglycemia.
Regular assessment for signs of tardive dyskinesia or extrapyramidal symptoms during prolonged therapy.
Avoid abrupt discontinuation to prevent withdrawal or rebound psychosis.
Ensure patients take lurasidone with food to maximize absorption and therapeutic effect.
Watch for mood changes or suicidal ideation, especially in younger populations.
Avoid use in older adults with dementia-related psychosis due to increased mortality risk.
Monitor for orthostatic hypotension; advise caution when standing up quickly.
Consider hepatic and renal function status when initiating and maintaining therapy.
Pregnancy and breastfeeding require risk-benefit evaluation; potential neonatal complications may occur.
Assess for drug interactions, particularly with CYP3A4 inhibitors and inducers.
Caution in patients with cardiovascular disease or history of stroke.
Inform patients about the risk of overheating and the importance of fluid intake, especially in hot climates.
Regular baseline and follow-up blood counts may be needed in patients with low white blood cell counts.
Use with caution in patients with thyroid or pituitary disorders.

Warnings

Not approved for use in older adults with dementia-related psychosis due to increased risk of death.
Potential for suicidal thoughts and behaviors, necessitating close monitoring.
Increased risk of serious movement disorders (e.g., tardive dyskinesia) with high doses or long-term use.
Risk of neuroleptic malignant syndrome, a potentially fatal condition, requiring immediate medical attention.
Avoid concomitant use with strong CYP3A4 inhibitors or inducers without dose adjustment or clinician supervision.
Risk of hyperglycemia and diabetes mellitus; monitor blood glucose regularly.
Potential for orthostatic hypotension, which may lead to falls or injuries.
Not recommended for use in patients with known hypersensitivity to lurasidone.
Abrupt discontinuation may precipitate withdrawal symptoms or relapse of psychosis.
May cause abnormal heart rhythms; use cautiously in patients with cardiac conduction abnormalities.
Elevated prolactin levels may occur, affecting menstrual cycle and sexual function.
Use with caution in patients at risk for seizures or with a history of stroke.
Avoid use with alcohol; may enhance CNS depression and impair motor skills.
Potential newborn complications when used during the last trimester of pregnancy.
May cause hematologic abnormalities including neutropenia and leukopenia.

Contraindication

Known hypersensitivity to lurasidone or any of its components.
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, voriconazole) without dose adjustment.
Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin).
Use in older adults with dementia-related psychosis due to increased mortality risk.
Pediatric patients under 13 years for schizophrenia and under 10 years for bipolar depression (lack of approval and safety data).
Patients with a history of neuroleptic malignant syndrome attributed to dopamine antagonists.
Known or suspected history of long QT syndrome or other cardiac arrhythmias that could be exacerbated.
Concurrent use with medications that prolong QT interval without careful monitoring.
Severe hepatic impairment without dose adjustment is contraindicated due to altered metabolism.
Patients who are breastfeeding unless benefits outweigh risks after physician consultation.
Concurrent use of lurasidone with opioids or other CNS depressants without careful oversight.
Patients with low white blood cell counts or immunosuppression without hematological monitoring.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, voriconazole) can increase lurasidone plasma concentrations, raising risk of toxicity.
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can reduce efficacy by decreasing lurasidone plasma levels.
Concomitant use with other CNS depressants, including opioids, benzodiazepines, and alcohol, may increase sedation and respiratory depression risks.
Concurrent administration with St. John's wort may reduce lurasidone levels via CYP3A4 induction.
Use with QT-prolonging drugs can enhance cardiac arrhythmia risk; monitoring is advised.
Drugs that lower seizure threshold (e.g., bupropion, tramadol) may increase seizure risk during lurasidone therapy.
Antihypertensives may have additive hypotensive effects causing orthostatic hypotension.
Agents affecting electrolyte balance, such as diuretics, can exacerbate cardiac risks with lurasidone.
Concurrent use with antidepressants metabolized by CYP3A4 may alter levels of either agent.
Interactions with antiretroviral drugs like ritonavir can increase or decrease lurasidone exposure.
Smoking cessation or initiation can alter CYP1A2 activity, which has less impact compared to CYP3A4 but may contribute to variability.
Concomitant use with other antipsychotics requires careful titration and monitoring for additive side effects.
Avoid grapefruit and grapefruit juice to prevent increased systemic exposure and side effects.
Drugs causing bone marrow suppression may compound hematologic side effects.
Careful monitoring when combined with seizure medications due to pharmacodynamic interactions.

Preparations Of The Drug

Oral tablets available in strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
Formulated for once-daily oral administration with food to enhance absorption.
Tablets designed to be swallowed whole; splitting or crushing is not recommended.
Packaging includes standard blister packs or bottles as per manufacturer specification.
Storage at room temperature, protected from moisture and heat to preserve stability.
No injectable or intravenous formulations currently available.
No extended-release or depot formulations on the market as of current data.
Available in prescription-only status with labeled indications for schizophrenia and bipolar depression.
Manufactured under strict GMP to comply with regulatory standards for safety and efficacy.
Patient information leaflets provided with all packaging to ensure correct usage.
Supplementary medication guides highlight the necessity of food during dosing and potential side effects.
Available with patient assistance programs or insurance formularies depending on region.
Not approved as a controlled substance; standard prescribing regulations apply.
Compatible with standard pharmaceutical compounding guidelines if needed for special cases (with physician oversight).
Stability and shelf-life data indicate normal expiration dating consistent with solid oral dosage forms.